# Daclizumab to Treat Non-Infectious Sight-Threatening Uveitis

> **NCT00070759** · PHASE2 · COMPLETED · sponsor: **National Eye Institute (NEI)** · enrollment: 6 (—)

## Conditions studied

- Uveitis

## Interventions

- **DRUG:** Daclizumab

## Key facts

- **NCT ID:** NCT00070759
- **Lead sponsor:** National Eye Institute (NEI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-10-06
- **Primary completion:** —
- **Final completion:** 2006-10-02
- **Target enrollment:** 6 (—)
- **Last updated:** 2017-07-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00070759

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00070759, "Daclizumab to Treat Non-Infectious Sight-Threatening Uveitis". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT00070759. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*